Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. - sprookjes - yvandenbroek - TriplyDB

Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.

Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.

http://www.wikidata.org/entity/Q34795242

about

Legal highs: staying on top of the flood of novel psychoactive substances Conversion of psychological stress into cellular stress response: roles of the sigma-1 receptor in the process Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy Allosteric Modulation of Sigma-1 Receptors Elicits Rapid Antidepressant Activity Potential Molecular Mechanisms on the Role of the Sigma-1 Receptor in the Action of Cocaine and Methamphetamine Stress-induced pain: a target for the development of novel therapeutics Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by ifenprodil: the role of sigma-1 and IP3 receptors Neuroprotective effects of high affinity Σ1 receptor selective compounds.Sigma-1 receptor chaperones in neurodegenerative and psychiatric disorders Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor The cognition-enhancing activity of E1R, a novel positive allosteric modulator of sigma-1 receptors Ether modifications to 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine (SA4503): effects on binding affinity and selectivity for sigma receptors and monoamine transporters.Sigma-1 receptors and animal studies centered on pain and analgesia.The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems.Sigma-1 receptor enhances neurite elongation of cerebellar granule neurons via TrkB signaling A Role for Sigma Receptors in Stimulant Self Administration and Addiction.The effects of sigma (σ1) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice.Antagonism of sigma-1 receptors blocks compulsive-like eating.The lifetime of UDP-galactose:ceramide galactosyltransferase is controlled by a distinct endoplasmic reticulum-associated degradation (ERAD) regulated by sigma-1 receptor chaperones The sigma-1 receptor: roles in neuronal plasticity and disease A role for sigma receptors in stimulant self-administration and addiction.Preface.Synthesis and σ1 Receptor Binding of Halogenated N,N'-Diphenethylethylenediamines.Beneficial effects of the sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 cases.Sigma receptors [σRs]: biology in normal and diseased states Sigma-1 receptor chaperones regulate the secretion of brain-derived neurotrophic factor.Sigma-1 receptor expression in sensory neurons and the effect of painful peripheral nerve injury.Sigma-1 Receptor Agonism Promotes Mechanical Allodynia After Priming the Nociceptive System with Capsaicin.The sigma-1 receptor: a regulator of cancer cell electrical plasticity?Selective sigma-1 receptor antagonists for the treatment of pain.The ON:OFF switch, σ1R-HINT1 protein, controls GPCR-NMDA receptor cross-regulation: implications in neurological disorders.Investigational sigma-1 receptor antagonists for the treatment of pain.Recent Advances in the Realm of Allosteric Modulators for Opioid Receptors for Future Therapeutics.Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.Allosteric modulation of sigma-1 receptors by SKF83959 inhibits microglia-mediated inflammation.Tactics for preclinical validation of receptor-binding radiotracers.Pathological Overeating: Emerging Evidence for a Compulsivity Construct.The essential roles of protein-protein interaction in sigma-1 receptor functions.Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses.Benefical effects of sigma-1 agonist fluvoxamine for tardive dyskinesia and tardive akathisia in patients with schizophrenia: report of three cases.

P2860

Q26799231-2B56AB8A-8F67-4B4A-A548-09D97A2F7486 Q27023681-A51D43A2-2A7C-4CBD-9AB4-426AF3A4BBCE Q27024227-BA3EF37E-003A-4F57-8D1B-23F249E22F54 Q28273055-B296DDFE-32B4-4AC0-9180-BF7514FAB2FA Q28392148-82899614-2A64-4664-8952-D53618A75B09 Q28654612-C483DC3B-85C9-410C-85B1-86019906AF43 Q28729237-45F6AAC1-B11A-4E00-986D-8E469E323D67 Q33745942-FCC7CD98-6D36-4651-9FB4-EFEBF8A6775B Q33920251-58FB13B7-0ADC-4FD3-95E6-9A22799EFFAA Q34007801-4821909B-BBAB-411F-A6AA-1A099E1E37A3 Q34401854-215C7A46-634A-4199-BBE3-1C371359D4EE Q34451737-35D37FD8-3D16-426E-A3CB-9A368FA8AA0B Q34670217-FCD01824-EB06-42BE-8741-ADB93601691E Q34675713-B60BDDF1-A384-45CB-B2CE-4662491AF20C Q35014550-345068F6-B517-4FE5-9838-0819A9F96A73 Q35197016-358884FF-90DC-4DA5-B231-4EF7B757B8C2 Q35538511-1196D680-856E-48DB-903B-8F0C7CF15A6B Q36323590-386D2D31-7415-4B85-9B04-E72B0B29183F Q36466836-B9D4112D-06DF-4ABE-A731-976AF95784FC Q36653400-AD867C23-A7E1-427E-8254-1AE83ECAB85A Q36655919-D319CCF2-722F-40AA-97F3-8A8BD5209901 Q36717105-881BDFB2-5E7C-4182-99AF-1281ADFB9991 Q36737209-6DC8668D-A651-48CF-9B98-D5F296DAED40 Q36755305-EC95CDC9-FCD1-44B7-B5B8-FF204928054F Q37000551-1A10BA90-A9E1-48B9-AF2C-88D28BBCB948 Q37300447-C39331DF-FDCD-4FBC-BCC4-D9E4DE55D24B Q37357665-46183C00-FA24-4276-A7CC-E73C736B9F26 Q37439130-77911A9A-8317-440C-9232-A1C628DA1AA4 Q38123807-4D3178B9-3C61-4D8E-9924-8BE6D3A451CB Q38235503-A59DC8BF-2464-4602-B745-D01360971136 Q38262682-D07F9089-D0A4-4A16-A363-66758D218E9D Q38513640-D200F856-1C36-47A0-94CC-7B43DDF86544 Q38736252-5F4DCA8F-4CCD-441E-ABD9-E8DDFBFCC1DC Q38861728-0DA97873-5EE8-4D9F-8BC0-2AAD5B5C25DF Q38868897-A205A4A0-2885-4264-AAF7-9918A28B8B7F Q38984519-5CC822CD-22F7-4948-BA86-D75EDEC13A85 Q39030561-976CBE9F-367E-496D-A233-3A6E153B6E52 Q40007694-6B39C718-A9B1-4ED4-A9E2-23A9B8B21E77 Q40753593-A2464A12-3B90-4AC1-B60A-AED747B74CA5 Q41891428-9583223E-F117-4CEA-84C0-B218E37EB4A4

P2860

Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.

http://www.wikidata.org/entity/Q34795242

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Targeting ligand-operated chap ...... of neuropsychiatric disorders.

@ast

Targeting ligand-operated chap ...... of neuropsychiatric disorders.

@en

Targeting ligand-operated chap ...... of neuropsychiatric disorders.

@nl

type

label

Targeting ligand-operated chap ...... of neuropsychiatric disorders.

@ast

Targeting ligand-operated chap ...... of neuropsychiatric disorders.

@en

Targeting ligand-operated chap ...... of neuropsychiatric disorders.

@nl

prefLabel

Targeting ligand-operated chap ...... of neuropsychiatric disorders.

@ast

Targeting ligand-operated chap ...... of neuropsychiatric disorders.

@en

Targeting ligand-operated chap ...... of neuropsychiatric disorders.

@nl

P1433

Q34795242-2518D1D3-382B-4A52-B03A-DE854C338F36

P1476

Q34795242-37E2346A-B14E-4851-A89D-C439C1C91737

P2093

Q34795242-57A4EB81-3DA2-444A-B407-33FDD398F1E4

Q34795242-B1458148-6BE6-4C38-AC91-A605D2C6B621

Q34795242-D2D5A7FE-8F2A-49B6-B95C-8FA22D8B9FCD

Q34795242-D50D93A5-6AFE-4053-94A6-DF34460E713F

Q34795242-E50F4950-62BF-4F61-A3E2-317FF80AC9C8

P2860

Q34795242-033D01CD-29DF-402F-A35C-F5CFACBD3AF9

Q34795242-0880DDB0-21E9-4007-9EE3-2F4BD0E5EBCF

Q34795242-0A7EEB29-C964-4312-B6B4-1B7732922DE7

Q34795242-0AD06E78-590D-4F5D-839B-33D1C39ED80A

Q34795242-0C326D0D-E666-4BFF-8450-F24B46087D0B

Q34795242-0EA51C73-BAAF-4EAC-B94B-53C7F4CF0E7A

Q34795242-0F08A059-9B74-4D4F-BE6A-A2BC57D9114E

Q34795242-11FD6EA4-E643-42E0-AF81-18E048EF8CB3

Q34795242-120165C2-DA42-4175-AA42-83F8D2434665

Q34795242-157D5084-D9AD-49D2-B001-7AE02BE81A60

P304

Q34795242-CBDF9D04-26E6-46A7-9E78-9947DEC99C31

P31

Q34795242-282B3AE8-9E72-43D1-B9E4-9179205B1F4E

P356

Q34795242-A200B4C7-82BB-4BE3-925F-25FC4F13B094

P407

Q34795242-3981536B-5EA3-48AE-A704-40FD93EF3FEE

P433

Q34795242-4E0164CB-4E3A-4809-8AA4-6DC8853F0FA1

P478

Q34795242-89410947-5E3C-4437-A00C-869232D312B2

P577

Q34795242-505E2FB8-0BC0-4B7B-A3B6-FCCDE883D610

P5875

Q34795242-0506640C-E295-4679-ADEF-8127ACD20B6E

P698

Q34795242-A2B3A020-1684-40B2-BA97-5ED54C2D57F1

P921

Q34795242-1B0C9B2A-64C3-4C04-9019-FC05ACF137D8

P932

Q34795242-BB5F5C5F-473B-403C-8C42-E1AC04D1FC18

P356

14728222.2011.560837

P1433

Expert Opinion on Therapeutic Targets

P1476

Targeting ligand-operated chap ...... of neuropsychiatric disorders.

@en

P2093

Michiko Fujimoto

http://www.w3.org/2001/XMLSchema#string

Shang-Yi Tsai

http://www.w3.org/2001/XMLSchema#string

Teruo Hayashi

http://www.w3.org/2001/XMLSchema#string

Tomohisa Mori

http://www.w3.org/2001/XMLSchema#string

Tsung-Ping Su

http://www.w3.org/2001/XMLSchema#string

P2860

Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation

Sigma receptors: potential targets for a new class of antidepressant drug

The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator

MAM: more than just a housekeeper

Sigma receptor agonists provide neuroprotection in vitro by preserving bcl-2

The sigma-receptor antagonist BD-1063 decreases ethanol intake and reinforcement in animal models of excessive drinking

Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine

No association between the sigma receptor type 1 gene and schizophrenia: results of analysis and meta-analysis of case-control studies

The Rac1-GEF Tiam1 couples the NMDA receptor to the activity-dependent development of dendritic arbors and spines

Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group

P304

557-577

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.2011.560837

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50286696

http://www.w3.org/2001/XMLSchema#string

P698

21375464

http://www.w3.org/2001/XMLSchema#string

P921

molecular chaperones

P932

3076924

http://www.w3.org/2001/XMLSchema#string